Curanex Pharmaceuticals (CURX) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Curanex Pharmaceuticals is the larger company by market cap ($7.5 million vs $7.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CURX | TRAW |
|---|---|---|
| Share price | $4.76 | $0.4803 |
| Market cap | $7.46M | $7.38M |
| 1-day change | -0.94% | +0.27% |
| EPS (TTM) | $-7.80 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.94 | $3.27 |
| 52-week low | $3.58 | $0.43 |
| Distance from 52-week high | -71.90% | -85.31% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +108.20% |
| Average volume | 19.85K | 569.02K |
| Shares outstanding | 1.57M | 15.37M |
| Employees | 6 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Curanex Pharmaceuticals
CURX stock →Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Healthcare · Biotechnology · 6 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Healthcare · Biotechnology · 4 employees
CURX vs TRAW FAQ
Which is bigger, Curanex Pharmaceuticals or Traws Pharma?
Curanex Pharmaceuticals (CURX) is larger, with a market capitalization of $7.46M compared with $7.38M for Traws Pharma (TRAW).
Are Curanex Pharmaceuticals and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.